Arming androgen receptors to oppose oncogenic estrogen receptor activity in breast cancer

Theresa E Hickey; Amy R Dwyer; Wayne D Tilley

doi:10.1038/s41416-021-01478-8

Arming androgen receptors to oppose oncogenic estrogen receptor activity in breast cancer

Br J Cancer. 2021 Dec;125(12):1599-1601. doi: 10.1038/s41416-021-01478-8. Epub 2021 Jul 22.

Authors

Theresa E Hickey¹, Amy R Dwyer¹, Wayne D Tilley²

Affiliations

¹ Dame Roma Mitchell Cancer Research Laboratories, Adelaide Medical School, University of Adelaide, Adelaide, SA, Australia.
² Dame Roma Mitchell Cancer Research Laboratories, Adelaide Medical School, University of Adelaide, Adelaide, SA, Australia. wayne.tilley@adelaide.edu.au.

Abstract

Most breast cancers are driven by oncogenic activity of the estrogen receptor alpha (ER). Resistance to ER target therapies is the major cause of breast cancer death. Recently, there has been renewed interest in targeting the androgen receptor (AR) to treat ER-driven breast cancers. Herein, we discuss evidence for an AR agonist, not antagonist, treatment strategy.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Breast Neoplasms / drug therapy*
Breast Neoplasms / genetics*
Female
Humans
Receptors, Androgen / metabolism*
Receptors, Estrogen / metabolism*

Substances

Receptors, Androgen
Receptors, Estrogen